In these patients, the complete pathological response after neoadjuvant chemotherapy was 53% with higher responders among HR-negative tumors when compared to HR-positive tumors (70% vs 39%); the HR-negative HER2 breast cancers were enriched in HER2-enriched tumors (75%) [90]. The gene discussed is ERBB2; the disease is breast cancer.